Allspring Global Investments Holdings LLC Purchases 71,872 Shares of Gilead Sciences, Inc. $GILD

Allspring Global Investments Holdings LLC increased its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 24.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 363,563 shares of the biopharmaceutical company’s stock after acquiring an additional 71,872 shares during the period. Allspring Global Investments Holdings LLC’s holdings in Gilead Sciences were worth $44,209,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also added to or reduced their stakes in GILD. Corundum Trust Company INC acquired a new stake in shares of Gilead Sciences in the 3rd quarter valued at $26,000. Howard Hughes Medical Institute bought a new position in shares of Gilead Sciences in the 2nd quarter valued at $30,000. MTM Investment Management LLC raised its holdings in shares of Gilead Sciences by 176.0% during the 3rd quarter. MTM Investment Management LLC now owns 276 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 176 shares in the last quarter. Kilter Group LLC bought a new stake in shares of Gilead Sciences during the 2nd quarter worth $33,000. Finally, Millstone Evans Group LLC boosted its stake in Gilead Sciences by 58.7% in the third quarter. Millstone Evans Group LLC now owns 319 shares of the biopharmaceutical company’s stock valued at $35,000 after buying an additional 118 shares in the last quarter. 83.67% of the stock is owned by institutional investors.

Insider Buying and Selling at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 3,000 shares of the stock in a transaction on Monday, March 16th. The stock was sold at an average price of $144.23, for a total value of $432,690.00. Following the completion of the sale, the chief financial officer directly owned 179,191 shares in the company, valued at $25,844,717.93. This represents a 1.65% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Jeffrey Bluestone sold 5,000 shares of the firm’s stock in a transaction on Tuesday, January 20th. The stock was sold at an average price of $123.50, for a total value of $617,500.00. Following the transaction, the director directly owned 8,920 shares of the company’s stock, valued at approximately $1,101,620. This represents a 35.92% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 299,280 shares of company stock worth $42,820,550 over the last ninety days. Insiders own 0.27% of the company’s stock.

Gilead Sciences Stock Performance

Shares of GILD stock opened at $140.30 on Thursday. The firm has a market capitalization of $174.14 billion, a price-to-earnings ratio of 20.72, a PEG ratio of 1.83 and a beta of 0.37. The company has a current ratio of 1.55, a quick ratio of 1.40 and a debt-to-equity ratio of 0.98. The business’s 50-day moving average price is $144.85 and its 200-day moving average price is $129.14. Gilead Sciences, Inc. has a 12 month low of $93.37 and a 12 month high of $157.29.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.83 by $0.03. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The company had revenue of $7.93 billion during the quarter, compared to the consensus estimate of $7.68 billion. During the same quarter in the prior year, the firm posted $1.90 earnings per share. The firm’s revenue was up 4.7% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. Equities research analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, March 30th. Stockholders of record on Friday, March 13th were paid a dividend of $0.82 per share. The ex-dividend date of this dividend was Friday, March 13th. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.79. This represents a $3.28 annualized dividend and a dividend yield of 2.3%. Gilead Sciences’s payout ratio is 48.45%.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on GILD shares. Scotiabank lifted their target price on Gilead Sciences from $140.00 to $177.00 and gave the company a “sector outperform” rating in a research report on Wednesday, February 11th. Wells Fargo & Company raised their price target on shares of Gilead Sciences from $150.00 to $165.00 and gave the company an “overweight” rating in a research note on Wednesday, February 11th. Morgan Stanley lifted their price target on shares of Gilead Sciences from $150.00 to $171.00 and gave the company an “overweight” rating in a report on Wednesday, February 11th. Wolfe Research upped their price objective on shares of Gilead Sciences from $155.00 to $170.00 and gave the stock an “outperform” rating in a research report on Thursday, February 12th. Finally, Argus increased their price objective on shares of Gilead Sciences from $135.00 to $165.00 and gave the company a “buy” rating in a research note on Thursday, February 19th. Twenty-four analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $157.62.

More Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead agreed to acquire Ouro Medicines and struck a binding collaboration with Galapagos to advance T‑cell engager programs for autoimmune diseases — a clear push to expand its pipeline into potentially high‑value biologics and diversify beyond core antiviral franchises, which supports longer‑term growth expectations. Gilead Expands Autoimmune Ambitions With Ouro Deal And Galapagos Collaboration
• Positive Sentiment: RBC noted decent patient persistence for Yeztugo (HIV prevention), indicating commercial uptake is intact even if market expansion is limited — positive for ongoing revenue stability from Gilead’s HIV portfolio. Gilead Sciences Shows Solid Early Yeztugo Persistence but Limited Market Expansion, RBC Says
• Neutral Sentiment: Analysts expect single‑digit EPS growth for Q1 2026 — modest growth that keeps expectations muted vs. high‑growth peers but aligns with Gilead’s guidance and stable cash generation. This sets tempered near‑term performance expectations. Gilead Sciences’s Q1 2026 Earnings: What to Expect
• Neutral Sentiment: Market roundups and earnings/transcript coverage show Gilead’s stock has risen in recent sessions but still lagged broader indices — reflecting investor caution despite positive headlines. These pieces mainly summarize momentum rather than introduce new catalysts. Gilead Sciences (GILD) Rises Yet Lags Behind Market: Some Facts Worth Knowing
• Neutral Sentiment: General investor commentary listing Gilead as an attractive dividend/ income name may support demand from income investors but is not an immediate catalyst for a large re‑rating. Markets Haven’t Changed. These 2 Cheap Dividends Still Rule
• Negative Sentiment: Gilead extended the tender offer for Arcellx at $115 plus a $5 CVR — the extension signals the deal hasn’t closed and increases short‑term uncertainty (and potential near‑term cash outflow). Investors may view extensions as a risk that the acquisition will be more costly, contested, or delayed. Gilead Extends Tender Offer to Acquire Arcellx

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.